SG10201914067XA - Humanized anti-tau antibodies - Google Patents

Humanized anti-tau antibodies

Info

Publication number
SG10201914067XA
SG10201914067XA SG10201914067XA SG10201914067XA SG10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA SG 10201914067X A SG10201914067X A SG 10201914067XA
Authority
SG
Singapore
Prior art keywords
humanized anti
tau antibodies
tau
antibodies
humanized
Prior art date
Application number
SG10201914067XA
Other languages
English (en)
Inventor
Tim West
Diljeet ATHWAL
Timothy Jones
Francis Carr
Robert Holgate
Original Assignee
C2N Diagnostics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C2N Diagnostics Llc filed Critical C2N Diagnostics Llc
Publication of SG10201914067XA publication Critical patent/SG10201914067XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
SG10201914067XA 2014-06-27 2015-06-26 Humanized anti-tau antibodies SG10201914067XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018436P 2014-06-27 2014-06-27
US201462080903P 2014-11-17 2014-11-17
US201562170036P 2015-06-02 2015-06-02

Publications (1)

Publication Number Publication Date
SG10201914067XA true SG10201914067XA (en) 2020-03-30

Family

ID=54938957

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201914067XA SG10201914067XA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies
SG11201610862VA SG11201610862VA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201610862VA SG11201610862VA (en) 2014-06-27 2015-06-26 Humanized anti-tau antibodies

Country Status (27)

Country Link
US (2) US9957317B2 (pt)
EP (1) EP3182987B1 (pt)
JP (3) JP6626892B2 (pt)
KR (1) KR102431596B1 (pt)
CN (1) CN106659759B (pt)
AU (2) AU2015279643B2 (pt)
BR (1) BR112016030686A2 (pt)
CA (2) CA3094638A1 (pt)
CL (1) CL2016003346A1 (pt)
CR (1) CR20170026A (pt)
DO (1) DOP2016000335A (pt)
EC (1) ECSP17005649A (pt)
ES (1) ES2959528T3 (pt)
IL (3) IL249734B (pt)
MA (1) MA40229A (pt)
MX (2) MX2017000205A (pt)
MY (1) MY184540A (pt)
NZ (1) NZ727919A (pt)
PE (1) PE20170665A1 (pt)
PH (2) PH12016502608A1 (pt)
RU (1) RU2743152C2 (pt)
SG (2) SG10201914067XA (pt)
TW (3) TW202136296A (pt)
UA (1) UA122771C2 (pt)
UY (1) UY36194A (pt)
WO (1) WO2015200806A2 (pt)
ZA (1) ZA201608875B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9834596B2 (en) 2012-07-03 2017-12-05 Washington University Antibodies to tau
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
TWI827405B (zh) 2015-06-05 2023-12-21 美商建南德克公司 抗-ｔａｕ抗體及使用方法
WO2016201434A2 (en) * 2015-06-12 2016-12-15 C2N Diagnostics, Llc Stable formulations of humanized anti-tau antibody
EP3445785B1 (en) 2016-04-18 2022-06-22 Faron Pharmaceuticals OY Humanized anti clever-1 antibodies and their use
CN109415432B (zh) * 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
KR20230070336A (ko) 2016-05-02 2023-05-22 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
UA124148C2 (uk) 2016-05-02 2021-07-28 Протена Біосайенсіс Лімітед Антитіла, що розпізнають тау
US10570196B2 (en) * 2016-07-20 2020-02-25 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
AU2017322656B2 (en) * 2016-09-10 2024-02-29 Yeda Research And Development Co. Ltd. Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20190054094A (ko) 2016-09-27 2019-05-21 세로 테라퓨틱스, 인코포레이티드 키메라 포식작용 수용체 분자
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
JP7193457B2 (ja) 2016-12-07 2022-12-20 ジェネンテック， インコーポレイテッド 抗ｔａｕ抗体及び使用方法
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
CN110494446A (zh) 2017-03-28 2019-11-22 基因泰克公司 治疗神经退行性疾病的方法
EP3619233A4 (en) 2017-05-02 2021-03-03 Prothena Biosciences Limited ANTIBODIES RECOGNIZING TAU PROTEIN
KR20200100598A (ko) 2017-09-26 2020-08-26 세로 테라퓨틱스, 인코포레이티드 키메라 포식작용 수용체 분자 및 사용 방법
GEP20227406B (en) 2017-10-02 2022-08-25 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
SG11202003392VA (en) * 2017-10-16 2020-05-28 Eisai R&D Man Co Ltd Anti-tau antibodies and uses thereof
EP3768706A1 (en) * 2018-03-23 2021-01-27 AbbVie Deutschland GmbH & Co. KG Stable aqueous anti-tau antibody formulations
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
CA3107933A1 (en) * 2018-08-01 2020-02-06 Imcheck Therapeutics Sas Anti-btn3a antibodies and their use in treating cancer or infectious disorders
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
CN114430744A (zh) * 2019-07-15 2022-05-03 阿德尔公司 抗Tau抗体及其用途
CA3148740A1 (en) 2019-08-06 2021-02-11 Aprinoia Therapeutics Limited Antibodies that bind to pathological tau species and uses thereof
EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
KR20240049296A (ko) 2021-08-27 2024-04-16 제넨테크, 인크. 타우 병증을 치료하는 방법
WO2023041805A1 (en) 2021-09-20 2023-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023178049A1 (en) 2022-03-14 2023-09-21 Genentech, Inc. Predicting neurodegenerative diseases based on speech analyses
WO2023250326A1 (en) 2022-06-21 2023-12-28 Genentech, Inc. Detecting longitudinal progression of alzheimer's disease (ad) based on speech analyses
CN115724970B (zh) * 2022-07-27 2023-10-20 生工生物工程（上海）股份有限公司 一种特异性结合e-cad多肽的结合蛋白及其应用
CN116375857A (zh) * 2023-03-30 2023-07-04 天津鸿宇泰生物科技有限公司 一种用于检测Tau蛋白的单链抗体及其制备方法和应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI884505A (fi) 1987-10-02 1989-04-03 Du Pont Immunoanalys, i vilken anvaends igg-uppsnappande antikroppar och detekteringssystem foer flera monoklonala antikroppar.
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JP3909084B2 (ja) 1991-10-25 2007-04-25 エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム 微小管結合タンパク質タウに対するモノクローナル抗体
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
DE69230148T2 (de) 1991-12-06 2000-05-04 Max Planck Gesellschaft Werkzeuge für die Diagnose und Behandlung der Alzheimerschen Krankheit.
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
JPH10506381A (ja) 1994-07-29 1998-06-23 イノジェネティックス・ナムローゼ・フェンノートシャップ 特定のサブクラスまたは形態のホスホリレーションされたｔａｕのエピトープに特異的なモノクローナル抗体、それらを分泌するハイブリドーマ、これらの抗体の抗原認識およびそれらの応用
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6797478B1 (en) 1998-03-05 2004-09-28 University Of Cincinnati Method of detecting axonal damage, from associated disease states using tau monoclonal antibodies
BR9913112A (pt) 1998-09-08 2001-05-08 Innogenetics Nv Tau como um marcador para dano inicial de cns
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6589746B1 (en) 1999-10-21 2003-07-08 University Of Cincinnati Method of detecting axonally-derived protein tau in patients with traumatic CNS injury
JP4582874B2 (ja) 2000-07-13 2010-11-17 富士通株式会社 偏波モード分散補償方法および偏波モード分散補償装置
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
WO2003057881A1 (fr) 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
LT1507556T (lt) 2002-05-02 2016-10-10 Wyeth Holdings Llc Kalicheamicino darinio ir nešiklio konjugatai
DE60323231D1 (de) 2002-07-12 2008-10-09 Axon Neuroscience Verkürzte tau proteine
EP1535930B1 (en) 2002-08-14 2010-10-06 Mitsubishi Chemical Medience Corporation Antibody specific to central nervous system tau protein
FI20030652A0 (fi) 2003-04-30 2003-04-30 Susann Eriksson Parannettu immunomääritys
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
WO2005073375A1 (en) * 2004-01-30 2005-08-11 Maxygen Holdings Ltd. Regulated stop codon readthrough
US7238788B2 (en) 2004-02-18 2007-07-03 University Of Iowa Foundation Antibodies to phosphorylated tau, methods of making and methods of use
KR20100036324A (ko) 2005-02-19 2010-04-07 주식회사 피플바이오 멀티머-형성 폴리펩타이드의 모노머로부터 멀티머를 분별 검출하는 방법
EP1940442A4 (en) 2005-08-04 2009-08-19 Einstein Coll Med PHOSPHORYLATION OF TAU BY ABL
ES2321996B1 (es) 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
ME00581B (me) * 2006-07-18 2011-12-20 Sanofi Aventis Antagonisticna antitijela za tretman kancera polje pronalaska
WO2008140639A2 (en) 2007-02-08 2008-11-20 Oligomerix, Inc. Biomarkers and assays for alzheimer's disease
NZ588555A (en) 2008-04-24 2012-06-29 Bristol Myers Squibb Co Use of epothilone d in treating tau-associated diseases including alzheimer's disease
CN101307108B (zh) 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
WO2010036959A2 (en) * 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
WO2010096751A1 (en) 2009-02-23 2010-08-26 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating a disease mediated by soluble oligomeric amyloid beta
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
WO2010129674A2 (en) 2009-05-05 2010-11-11 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2440234A4 (en) 2009-06-10 2013-11-06 Univ New York IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS
JP5370780B2 (ja) 2009-06-17 2013-12-18 株式会社フジクラ マルチクラッド光ファイバ、光ファイバモジュール、ファイバレーザ及びファイバアンプ
IN2012DN00446A (pt) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
WO2011026031A1 (en) 2009-08-28 2011-03-03 The Board Of Regents Of The University Of Texas System Antibodies that bind tau oligomers
US8648044B2 (en) 2009-09-24 2014-02-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) FKBP52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction
WO2011109112A2 (en) 2010-03-05 2011-09-09 Albert Einstein College Of Medicine Of Yeshiva University Method of detecting tau protein and tau fragments in serum
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
AU2013205313B2 (en) 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
EP2987807A3 (en) 2010-10-07 2016-06-01 AC Immune S.A. Antibodies recognising phospho-tau
LT2627672T (lt) * 2010-10-11 2018-12-10 Biogen International Neuroscience Gmbh Žmogaus antikūnai prieš tau baltymą
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
US8697076B2 (en) 2011-04-27 2014-04-15 Northwestern University Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
US20120321594A1 (en) 2011-05-06 2012-12-20 New York University Methods of controlling axon or dendrite development of neuronal cells
EP2709728B1 (en) 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013012811A2 (en) 2011-07-19 2013-01-24 New York University Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides
ES2656442T3 (es) 2011-09-19 2018-02-27 Axon Neuroscience Se Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer
JP6358953B2 (ja) 2011-10-07 2018-07-18 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
WO2013063086A1 (en) 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
BR112014009962A2 (pt) * 2011-10-27 2019-09-24 Nkt Therapeutics Inc anticorpos humanizados para inkt
HUE045656T2 (hu) 2011-12-20 2020-01-28 Janssen Biotech Inc PHF-tau elleni ellenanyagok és alkalmazásuk
US20130251731A1 (en) * 2012-03-22 2013-09-26 The Trustees Of The University Of Pennsylvania Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies
EP2834270B1 (en) 2012-04-05 2019-10-30 AC Immune S.A. Humanized tau antibody
WO2013177104A2 (en) 2012-05-21 2013-11-28 Felder Mitchell S Treatment for tauopathies
PT2857039T (pt) * 2012-05-31 2020-01-07 Teijin Pharma Ltd Agente terapêutico ou profilático para demência
US9834596B2 (en) * 2012-07-03 2017-12-05 Washington University Antibodies to tau
BR112015003326A2 (pt) * 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
WO2014031697A2 (en) 2012-08-21 2014-02-27 The Institute Of Molecular Medicine COMPOSITIONS AND METHODS RELATED TO DISEASES ASSOCIATED WITH DEPOSITS OF AMYLOID, TAU, AND α-SYNUCLEIN
CA2887933A1 (en) 2012-10-12 2014-04-17 Arizona Board Of Agents, On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
WO2014089104A1 (en) * 2012-12-03 2014-06-12 Washington University Method for detection of aggregates in biological samples
US8921150B2 (en) 2012-12-06 2014-12-30 Taiwan Semiconductor Manufacturing Co., Ltd. Process to achieve contact protrusion for single damascene via
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
AU2013361107B2 (en) 2012-12-21 2018-08-23 Biogen International Neuroscience Gmbh Human anti-tau antibodies
WO2014096321A1 (en) 2012-12-21 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
ES2766762T3 (es) 2013-03-13 2020-06-15 Prothena Biosciences Ltd Inmunoterapia contra Tau
WO2014159244A2 (en) 2013-03-14 2014-10-02 Merck Patent Gmbh O-GlcNAc TAU ANTIBODY AND USE THEREOF
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
MX2015012872A (es) 2013-03-15 2016-02-03 Ac Immune Sa Anticuerpos anti-tau y metodos de uso.
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體

Also Published As

Publication number Publication date
ECSP17005649A (es) 2018-04-30
KR102431596B1 (ko) 2022-08-12
JP2020054356A (ja) 2020-04-09
CN106659759A (zh) 2017-05-10
RU2017102514A (ru) 2018-07-31
IL273656B (en) 2022-01-01
JP2022050392A (ja) 2022-03-30
EP3182987A4 (en) 2018-01-24
PE20170665A1 (es) 2017-06-10
MX2021008888A (es) 2021-08-19
EP3182987A2 (en) 2017-06-28
CR20170026A (es) 2017-06-16
MA40229A (fr) 2021-06-02
CA3094638A1 (en) 2015-12-30
MY184540A (en) 2021-04-01
CA2953809C (en) 2020-09-29
DOP2016000335A (es) 2017-04-17
PH12016502608A1 (en) 2017-04-24
CL2016003346A1 (es) 2017-07-21
TWI734975B (zh) 2021-08-01
US20180371066A1 (en) 2018-12-27
AU2015279643B2 (en) 2021-04-08
TW201946931A (zh) 2019-12-16
IL249734A0 (en) 2017-02-28
EP3182987B1 (en) 2023-09-27
MX2017000205A (es) 2017-08-22
JP6626892B2 (ja) 2019-12-25
KR20170026390A (ko) 2017-03-08
RU2743152C2 (ru) 2021-02-15
TW201607956A (zh) 2016-03-01
CN106659759B (zh) 2022-04-15
PH12021550023A1 (en) 2021-12-13
CA2953809A1 (en) 2015-12-30
ES2959528T3 (es) 2024-02-26
WO2015200806A3 (en) 2016-02-25
UY36194A (es) 2016-01-29
RU2017102514A3 (pt) 2019-02-25
AU2021204800A1 (en) 2021-08-05
US20170058024A1 (en) 2017-03-02
JP2017521097A (ja) 2017-08-03
TW202136296A (zh) 2021-10-01
WO2015200806A2 (en) 2015-12-30
IL249734B (en) 2020-03-31
UA122771C2 (uk) 2021-01-06
EP3182987C0 (en) 2023-09-27
SG11201610862VA (en) 2017-01-27
IL273656A (en) 2020-05-31
BR112016030686A2 (pt) 2017-10-31
AU2015279643A1 (en) 2017-01-19
NZ727919A (en) 2021-07-30
IL288649A (en) 2022-02-01
ZA201608875B (en) 2017-09-27
US9957317B2 (en) 2018-05-01
TWI664190B (zh) 2019-07-01

Similar Documents

Publication Publication Date Title
IL288649A (en) Human antibodies against tau
ZA201803874B (en) Humanized anti-cd73 antibodies
IL250583A0 (en) Anti-tigit antibodies
SG11201703403TA (en) Anti-tim-3 antibodies
SG11201703346PA (en) Anti-tim-3 antibodies
HK1258375A1 (zh) 人源化抗-cll-1抗體
IL256579A (en) Human antibodies
IL252422A0 (en) Effector-deficient anti-cd32a antibodies
PT3101131T (pt) Anticorpo antitranstirretina humanizado
IL262776A (en) Human anti-il-1r3 antibodies
IL250374B (en) Antibodies against ceramide
EP3131581A4 (en) Humanized anti-tf-antigen antibodies
IL246603B (en) A new antibody against netrin-1
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
IL247988A0 (en) Antibodies against hpa–1a
GB201419092D0 (en) Anti-TIM-3 antibodies
GB201419089D0 (en) Anti-TIM-3 antibodies
GB201417614D0 (en) Antibodies
GB201414270D0 (en) Antibodies
GB201405775D0 (en) Antibodies
GB201401200D0 (en) Antibodies